Du Chengrun, Ying Hongmei, Zhang Youwang, Huang Yafang, Zhai Ruiping, Hu Chaosu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Oncotarget. 2017 Jun 27;8(26):42372-42381. doi: 10.18632/oncotarget.16344.
Background and Objetive: To evaluate treatment outcomes for patients with retropharyngeal metastatic undifferentiated squamous cell carcinoma (SCC) from an unknown primary site.
From January 2005 to January 2015, patients who presented with enlarged retropharyngeal nodes underwent transoral sonography-guided fine-needle aspiration to confirm histology. Those with metastatic undifferentiated SCC with unknown primary tumors were treated with radical radiotherapy to nasopharyngeal mucosa plus bilateral neck. Chemotherapy was administered for patients staged N2-3. Endpoints included metastatic nodes control, the appearance of primary tumor, overall survival and treatment-related toxicities.
A total of 49 patients were recruited into this study. Retropharyngeal and cervical nodal disease was controlled in 96% of all patients. The incidence of occult primary cancer appearance was 8%. No primary cancer other than of the nasopharynx was detected during the course of follow-up. Ten patients developed distant metastases. The 5-year overall survival, progression-free survival, regional relapse free survival, distant metastasis free survival were 79.6%, 61.1%, 83.4%, 73.8%, respectively. Common late adverse effects included xerostomia (57%) and hearing impairment (35%).
Radical radiotherapy to both the nasopharynx and bilateral neck can achieve excellent outcome with mild toxicities for patients with retropharyngeal metastatic undifferentiated squamous cell carcinoma from an unknown primary site.
背景与目的:评估原发部位不明的咽后转移性未分化鳞状细胞癌(SCC)患者的治疗效果。
2005年1月至2015年1月,对出现咽后淋巴结肿大的患者进行经口超声引导下细针穿刺以确诊组织学类型。对原发肿瘤不明的转移性未分化SCC患者,采用对鼻咽黏膜加双侧颈部进行根治性放疗。N2-3期患者给予化疗。观察终点包括转移性淋巴结控制情况、原发肿瘤的出现情况、总生存率和治疗相关毒性。
本研究共纳入49例患者。96%的患者咽后和颈部淋巴结疾病得到控制。隐匿性原发癌出现率为8%。随访期间未检测到除鼻咽癌以外的其他原发癌。10例患者发生远处转移。5年总生存率、无进展生存率、区域无复发生存率、远处无转移生存率分别为79.6%、61.1%、83.4%、73.8%。常见的晚期不良反应包括口干(57%)和听力障碍(35%)。
对原发部位不明的咽后转移性未分化鳞状细胞癌患者,对鼻咽和双侧颈部进行根治性放疗可取得良好效果,且毒性轻微。